Healthcare / Diagnostics & ResearchTokyo
$1093.00
-20.00 (-1.80%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 34% · confianza 16%
FCF escenarios
weak_data · normalized FCF $-3.9B · quality 33.7/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
42/100
C
Piotroski
4/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$45.5B
P/E
10.0x
↓EV/EBITDA
7.7x
↓ROE
12.3%
↑Gross Margin
52.3%
↑Debt/Equity
0.86
↑TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
+22.2%
FCF CAGR
—
FCF margin
-12.0%
FCF / Net income
-0.79x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $32.41B · net income $4.92B · FCF $-3.90B
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $32.41B | $32.41B | $26.45B | $25.09B | $17.75B |
| Net Income | $4.92B | $4.92B | $5.53B | $6.06B | $7.13B |
| EBITDA | $8.83B | $8.83B | $8.98B | $9.49B | $9.49B |
| EPS | 118.29 | 118.29 | 132.86 | 145.56 | — |
| Gross Margin | 52.3% | 52.3% | 54.0% | 52.0% | 54.6% |
| Operating Margin | 9.2% | 9.2% | 15.7% | 20.9% | 23.6% |
| Net Margin | 15.2% | 15.2% | 20.9% | 24.2% | 40.2% |
| Balance Sheet | |||||
| Debt/Equity | 0.86 | 0.86 | 0.77 | 0.72 | 0.47 |
| Current Ratio | 1.09 | 1.09 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $-3.90B | $-3.90B | $-6.50B | $-951.7M | $4.34B |
| Returns | |||||
| ROE | 12.3% | 12.3% | 16.2% | 23.1% | 36.4% |
| Valuation | |||||
| P/E | 9.96 | 9.96 | 10.91 | 18.69 | — |
| EV/EBITDA | 7.70 | 7.70 | 8.49 | 12.81 | 7.50 |
| P/B | 1.14 | 1.14 | 1.77 | 4.32 | 3.51 |
| Growth & Yield | |||||
| Revenue Growth | 22.5% | 22.5% | 5.4% | 41.4% | — |
| EPS Growth | -11.0% | -11.0% | -8.7% | — | — |
| Dividend Yield | 4.5% | 4.5% | — | — | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
3Y implied EPS CAGR
-6.4%
EPS terminal req.
$96.99
Spread vs growth
-4.6%
5Y implied EPS CAGR
-0.2%
EPS terminal req.
$117.35
Spread vs growth
-10.8%
10Y implied EPS CAGR
4.8%
EPS terminal req.
$189.00
Spread vs growth
-15.8%
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-10.0%
Start / end P/E
9.6x → 9.2x
EPS bridge
132.86 → 118.29
Residual
+0.4%
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.